P-Selectin de-ACTIVation in COVID-19: What Have We Learned?
作者信息
Bikdeli Behnood, Eikelboom John W
机构信息
Thrombosis Research Group (B.B.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Cardiovascular Medicine Division (B.B.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
出版信息
Circulation. 2023 Aug;148(5):391-393. doi: 10.1161/CIRCULATIONAHA.123.065619. Epub 2023 Jul 31.
Abstract
摘要
相似文献
1
P-Selectin de-ACTIVation in COVID-19: What Have We Learned?新冠病毒肺炎中P-选择素的失活：我们学到了什么？
Circulation. 2023 Aug;148(5):391-393. doi: 10.1161/CIRCULATIONAHA.123.065619. Epub 2023 Jul 31.
2
Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial.西尼莫司单抗对 COVID-19 住院患者器官支持生存的影响：一项随机对照试验。
Circulation. 2023 Aug;148(5):381-390. doi: 10.1161/CIRCULATIONAHA.123.065190. Epub 2023 Jun 25.
3
Leukocyte adhesion to P-selectin and the inhibitory role of Crizanlizumab in sickle cell disease: A standardized microfluidic assessment.白细胞与 P-选择素的黏附作用及 Crizanlizumab 在镰状细胞病中的抑制作用：标准化微流控评估。
Blood Cells Mol Dis. 2020 Jul;83:102424. doi: 10.1016/j.bcmd.2020.102424. Epub 2020 Mar 10.
4
Crizanlizumab: First Approval.西尼兰单抗：首次获批
Drugs. 2020 Jan;80(1):79-84. doi: 10.1007/s40265-019-01254-2.
5
A critical evaluation of crizanlizumab for the treatment of sickle cell disease.对治疗镰状细胞病的 crizanlizumab 的评价。
Expert Rev Hematol. 2022 Jan;15(1):5-13. doi: 10.1080/17474086.2022.2023007. Epub 2021 Dec 30.
6
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial.P-选择素抑制剂克唑单抗在新型冠状病毒肺炎中的作用：一项安慰剂对照随机试验
JACC Basic Transl Sci. 2021 Dec;6(12):935-945. doi: 10.1016/j.jacbts.2021.09.013. Epub 2021 Dec 8.
7
Population Pharmacokinetics and Pharmacodynamics of Crizanlizumab in Healthy Subjects and Patients with Sickle Cell Disease.健康受试者和镰状细胞病患者中 crizanlizumab 的群体药代动力学和药效学。
Clin Pharmacokinet. 2023 Feb;62(2):249-266. doi: 10.1007/s40262-022-01193-4. Epub 2022 Dec 18.
8
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.克立硃单抗用于预防镰状细胞病的疼痛危象
N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3.
9
Plant-Produced Therapeutic Crizanlizumab Monoclonal Antibody Binds P-Selectin to Alleviate Vaso-occlusive Pain Crises in Sickle Cell Disease.植物生产的治疗性克立硐珠单抗单克隆抗体结合P-选择素以减轻镰状细胞病的血管闭塞性疼痛危机。
Mol Biotechnol. 2025 Mar;67(3):834-844. doi: 10.1007/s12033-024-01110-z. Epub 2024 Mar 15.
10
Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis.西利单抗治疗镰状细胞病患者亚组疼痛危象的效果：SUSTAIN 研究分析。
Am J Hematol. 2019 Jan;94(1):55-61. doi: 10.1002/ajh.25308. Epub 2018 Nov 25.
本文引用的文献
1
Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial.西尼莫司单抗对 COVID-19 住院患者器官支持生存的影响：一项随机对照试验。
Circulation. 2023 Aug;148(5):381-390. doi: 10.1161/CIRCULATIONAHA.123.065190. Epub 2023 Jun 25.
2
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial.秋水仙碱联合利伐沙班和阿司匹林治疗 COVID-19 住院患者（ACT）：一项开放标签、析因、随机、对照临床试验。
Lancet Respir Med. 2022 Dec;10(12):1169-1177. doi: 10.1016/S2213-2600(22)00298-3. Epub 2022 Oct 10.
3
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT.新冠肺炎危重症患者抗凝和抗血小板治疗预防静脉和动脉血栓栓塞事件的研究（COVID-PACT）
Circulation. 2022 Nov;146(18):1344-1356. doi: 10.1161/CIRCULATIONAHA.122.061533. Epub 2022 Aug 29.
4
Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial.重症 COVID-19 患者中阿托伐他汀与安慰剂的对比：随机对照试验。
BMJ. 2022 Jan 7;376:e068407. doi: 10.1136/bmj-2021-068407.
5
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial.P-选择素抑制剂克唑单抗在新型冠状病毒肺炎中的作用：一项安慰剂对照随机试验
JACC Basic Transl Sci. 2021 Dec;6(12):935-945. doi: 10.1016/j.jacbts.2021.09.013. Epub 2021 Dec 8.
6
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.COVID-19 患者住院期间使用阿司匹林（RECOVERY）：一项随机、对照、开放标签、平台试验。
Lancet. 2022 Jan 8;399(10320):143-151. doi: 10.1016/S0140-6736(21)01825-0. Epub 2021 Nov 17.
7
Use of novel antithrombotic agents for COVID-19: Systematic summary of ongoing randomized controlled trials.新型抗血栓药物在 COVID-19 中的应用：正在进行的随机对照试验的系统综述。
J Thromb Haemost. 2021 Dec;19(12):3080-3089. doi: 10.1111/jth.15533. Epub 2021 Sep 30.
8
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.不同预防性抗凝剂量方案在 COVID-19 危重症和非危重症患者中的安全性和有效性：一项随机对照试验的系统评价和荟萃分析。
Eur Heart J Cardiovasc Pharmacother. 2022 Sep 29;8(7):677-686. doi: 10.1093/ehjcvp/pvab070.
9
Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19.内皮功能障碍和免疫血栓形成是 COVID-19 的关键发病机制。
Nat Rev Immunol. 2021 May;21(5):319-329. doi: 10.1038/s41577-021-00536-9. Epub 2021 Apr 6.
10
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review.近期 COVID-19 患者抗血栓治疗的随机临床试验：美国心脏病学会最新综述。
J Am Coll Cardiol. 2021 Apr 20;77(15):1903-1921. doi: 10.1016/j.jacc.2021.02.035. Epub 2021 Mar 16.
Zotero 插件